chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 34.0
Sex: M
Vaccine: COVID19
Symptoms: Arthralgia, Chills, Hot flush, Pain, Pyrexia
Clinical narrative: Chills/heat flash 16+ hours after shot.; Chills/heat flash 16+ hours after shot.; Low grade fever, body/joint pains onset +12 hours after shot; Low grade fever, body/joint pains onset +12 hours after shot; Low grade fever, body/joint pains onset +12 hours after shot.; This is a spontaneous report from a contactable consumer, the patient. A 34-year-old male patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8737) via an unspecified route of administration in the left arm on 02Apr2021 at 08:15 (at the age of 34-years-old) as a single dose for COVID-19 immunisation. Medical history included inappropriate sinus tachycardia. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications were not reported. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 02Apr2021 at 20:15, the patient experienced low grade fever, body pains, joint pains with onset of plus 12 hours after shot. The patient also experienced chills, heat flash 16 plus hours after shot on 03Apr2021. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events low grade fever, chills, heat flash was resolved on an unknown date in Apr2021 plus 24 hours after shot, while that of body pains, joint pains was resolved on an unknown date in Apr2021 plus 36 hours after shot. The patient also received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8736) via an unspecified route of administration in the left arm on 23Apr2021 at 08:15 (at the age of 34-years-old) as a single dose for COVID-19 immunisation.  No follow-up attempts are needed. No further information is expected.
Age: 57.0
Sex: F
Vaccine: COVID19
Symptoms: Allodynia, Vaccination site erythema, Vaccination site pain, Vaccination site warmth
Clinical narrative: Extreme redness, warm, tenderness and allodynia type response starting at the puncture site and spreading 4 to 7 mm out across.; Extreme redness, warm, tenderness and allodynia type response starting at the puncture site and spreading 4 to 7 mm out across.; Extreme redness, warm, tenderness and allodynia type response starting at the puncture site and spreading 4 to 7 mm out across.; Extreme redness, warm, tenderness and allodynia type response starting at the puncture site and spreading 4 to 7 mm out across.; This is a spontaneous report from a contactable consumer, the patient. A 57-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0164) via an unspecified route of administration in the left arm on 21Apr2021 at 10:00 (at the age of 57-years-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19. The patient had no known allergies. Prior to vaccination, the patient was diagnosed with COVID-19. Concomitant medications included estradiol (MANUFACTURER UNKNOWN), medroxyprogesterone (MANUFACTURER UNKNOWN), zinc (MANUFACTURER UNKNOWN), ergocalciferol (VIT D) and azithromycin (Z-PAK); all from unknown dates for unknown indications and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8732) via an unspecified route of administration in the left arm on 31Mar2021 at 10:45 (at the age of 57-years-old) as a single dose for COVID-19 immunisation. On 22Apr2021 at 18:30, the patient experienced COVID arm extreme redness, warm, tenderness and allodynia type response starting at the puncture site and spreading 4 to 7 mm out across. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events extreme redness, warm, tenderness and allodynia type response were not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 29.0
Sex: F
Vaccine: COVID19
Symptoms: Arthritis
Clinical narrative: Intense flare up of my arthritis in my entire arm; This is a spontaneous report from a contactable consumer, the patient. A 29-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the arm on 17Apr2021 at 16:00 (at the age of 29-years-old) as a single dose for COVID-19 immunisation. Medical history included inflammatory arthritis and known allergy to MRI dye. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included duloxetine hydrochloride (CYMBALTA) for unknown indication from an unknown date and unknown if ongoing. The patient has been in remission from inflammatory arthritis for 2 years and on 24Apr2021 at 21:00, the patient had an acute but intense flare up of arthritis in entire arm, the same arm vaccine was in. It lasted around 12 hours. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event "intense flare up of my arthritis in my entire arm, the same arm vaccine was in" was resolved on 25Apr2021.   No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 74.0
Sex: F
Vaccine: COVID19
Symptoms: Peripheral swelling
Clinical narrative: Feet swollen; This is a spontaneous report from a contactable consumer, the patient. A 74-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 18Mar2021 at 14:00 (at the age of 74-years-old) as a single dose for COVID-19 immunisation. Medical history included rheumatoid arthritis (RA), asthma, lupus and allergy to sulfa. Concomitant medications included prednisone (MANUFACTURER UNKNOWN), gabapentin (MANUFACTURER UNKNOWN), apixaban (ELIQUIS), magnesium (MANUFACTURER UNKNOWN), calcium (MANUFACTURER UNKNOWN) and colecalciferol (VITAMIN D3): all from unknown dates for unknown indications and unknown if ongoing. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 03Apr2021 at 09:00 the patient experienced feet swollen. It was still swollen on 25Apr2021. The event resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of the event feet swollen which included compression socks to no avail. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event feet swollen was not resolved at the time of the report.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 47.0
Sex: F
Vaccine: COVID19
Symptoms: Myalgia
Clinical narrative: Severe muscle soreness left hip & thigh; This is a spontaneous report from a contactable consumer, the patient. A 47-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0150) via an unspecified route of administration in the left arm on 02Apr2021 at 12:45 (at the age of 47-years-old) and a second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8735) via an unspecified route of administration in the right arm on 23Apr2021 at 12:45 (at the age of 47-years-old) as a single dose for COVID-19 immunisation. Medical history included hypothyroidism. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient had received medication (unspecified) within two weeks of vaccination on an unknown date for unknown indication and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 03Apr2021 at 10:00, the patient experienced severe muscle soreness in left hip and thigh. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event severe muscle soreness in left hip and thigh was resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 37.0
Sex: F
Vaccine: COVID19
Symptoms: Amnesia, Arthralgia, Diarrhoea, Disturbance in attention, Feeling abnormal
Clinical narrative: Neck and arm pain shooting down to the hand; Neck and arm pain shooting down to the hand; Severe Headaches; Twitching of left hand; Blurry vision; Fog headed; Unable to focus; Body and joint pain; Body and joint pain; Memory loss; Nausea; Vomiting; Diarrhea; This is a spontaneous report from a contactable nurse, the patient. A 37-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via intramuscular route of administration in the left arm on 14Apr2021 at 13:00 (at the age of 37-years-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19. Prior to the vaccination, the patient was diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included iron chew (MANUFACTURER UNKNOWN) and vitamins (MANUFACTURER UNKNOWN), all for an unknown indication from an unknown date and unknown if ongoing. The patient previously took prochlorperazine edisylate (COMPAZINE) and metoclopramide (REGLAN) for unknown indication on an unknown date and experienced drug allergy. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via intramuscular route of administration in the left arm on 17Mar2021 at 13:00 (at the age of 37-years-old) as a single dose for COVID-19 immunisation. On 14Apr2021 at 14:00, the patient experienced neck and arm pain shooting down to the hand, severe headaches, twitching of left hand, blurry vision, fog headed, unable to focus, body and joint pain, memory loss, nausea, vomiting and diarrhea. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were not taken as a result of the events. Since the vaccination, it was unknown whether the patient had been tested for COVID-19. The clinical outcome of the events neck and arm pain shooting down to the hand, severe headaches, twitching of left hand, blurry vision, fog headed, unable to focus, body and joint pain, memory loss, nausea, vomiting and diarrhea was not resolved at the time of this report.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 37.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Muscle twitching, Nausea, Neck pain, Pain
Clinical narrative: Neck and arm pain shooting down to the hand; Neck and arm pain shooting down to the hand; Severe Headaches; Twitching of left hand; Blurry vision; Fog headed; Unable to focus; Body and joint pain; Body and joint pain; Memory loss; Nausea; Vomiting; Diarrhea; This is a spontaneous report from a contactable nurse, the patient. A 37-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via intramuscular route of administration in the left arm on 14Apr2021 at 13:00 (at the age of 37-years-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19. Prior to the vaccination, the patient was diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included iron chew (MANUFACTURER UNKNOWN) and vitamins (MANUFACTURER UNKNOWN), all for an unknown indication from an unknown date and unknown if ongoing. The patient previously took prochlorperazine edisylate (COMPAZINE) and metoclopramide (REGLAN) for unknown indication on an unknown date and experienced drug allergy. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via intramuscular route of administration in the left arm on 17Mar2021 at 13:00 (at the age of 37-years-old) as a single dose for COVID-19 immunisation. On 14Apr2021 at 14:00, the patient experienced neck and arm pain shooting down to the hand, severe headaches, twitching of left hand, blurry vision, fog headed, unable to focus, body and joint pain, memory loss, nausea, vomiting and diarrhea. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were not taken as a result of the events. Since the vaccination, it was unknown whether the patient had been tested for COVID-19. The clinical outcome of the events neck and arm pain shooting down to the hand, severe headaches, twitching of left hand, blurry vision, fog headed, unable to focus, body and joint pain, memory loss, nausea, vomiting and diarrhea was not resolved at the time of this report.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 37.0
Sex: F
Vaccine: COVID19
Symptoms: Pain in extremity, Vision blurred, Vomiting
Clinical narrative: Neck and arm pain shooting down to the hand; Neck and arm pain shooting down to the hand; Severe Headaches; Twitching of left hand; Blurry vision; Fog headed; Unable to focus; Body and joint pain; Body and joint pain; Memory loss; Nausea; Vomiting; Diarrhea; This is a spontaneous report from a contactable nurse, the patient. A 37-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via intramuscular route of administration in the left arm on 14Apr2021 at 13:00 (at the age of 37-years-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19. Prior to the vaccination, the patient was diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included iron chew (MANUFACTURER UNKNOWN) and vitamins (MANUFACTURER UNKNOWN), all for an unknown indication from an unknown date and unknown if ongoing. The patient previously took prochlorperazine edisylate (COMPAZINE) and metoclopramide (REGLAN) for unknown indication on an unknown date and experienced drug allergy. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via intramuscular route of administration in the left arm on 17Mar2021 at 13:00 (at the age of 37-years-old) as a single dose for COVID-19 immunisation. On 14Apr2021 at 14:00, the patient experienced neck and arm pain shooting down to the hand, severe headaches, twitching of left hand, blurry vision, fog headed, unable to focus, body and joint pain, memory loss, nausea, vomiting and diarrhea. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were not taken as a result of the events. Since the vaccination, it was unknown whether the patient had been tested for COVID-19. The clinical outcome of the events neck and arm pain shooting down to the hand, severe headaches, twitching of left hand, blurry vision, fog headed, unable to focus, body and joint pain, memory loss, nausea, vomiting and diarrhea was not resolved at the time of this report.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 51.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Tinnitus
Clinical narrative: Severe Tinnitus; Chronic fatigue; This is a spontaneous report from a contactable other health care professional, the patient. A 51-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER1734) via an unspecified route of administration in the left arm on 09Apr2021 at 20:00 (at the age of 51-year-old), as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient previously received pethidine hydrochloride (DEMEROL) for unspecified indication from unknown date and experienced drug allergy. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: ER7534) via an unspecified route of administration on the left arm on 19Mar2021 at 20:00 (at the age of 51-year-old), as a single dose for COVID-19 immunisation. On 10Apr2021, the patient experienced severe tinnitus and chronic fatigue. The events did not result in a visit to the doctors or other healthcare professional office/clinic, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events severe tinnitus and chronic fatigue was not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 30.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Diarrhoea, Myalgia, Pyrexia, Vomiting
Clinical narrative: Diarrhea; Vomiting; Fever; Muscle pain; Joint pain; This is a spontaneous report from a contactable consumer, the patient. A 30-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0170) via an unspecified route of administration on 22Apr2021 (at the age of 30-year-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On an unknown date in Apr2021, the patient experienced diarrhea, vomiting, fever, muscle pain and joint pain. On 25Apr2021, the patient underwent nasal swab test and the result was negative. Since the vaccination, the patient had been tested for COVID-19. The clinical outcome of the events diarrhea, vomiting, fever, muscle pain and joint pain was recovering at the time of report.   No follow-up attempts are needed. No further information is expected.
Age: 36.0
Sex: M
Vaccine: COVID19
Symptoms: Arthralgia, Back pain, Body temperature, Fatigue, Insomnia
Clinical narrative: Sore muscles; Aching joints; Congestion; Sore back; Fever (101.8 was the highest reading); Constant tiredness; Inability to sleep at night; This is a spontaneous report from a contactable consumer, the patient. A 36-year-old male patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Ew0158) via an unspecified route of administration in the left arm  on 21Apr2021 at 20:30 (at the age of 36-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history and no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Concomitant medications were not reported. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Er8737) via an unspecified route of administration in the left arm on 31Mar2021 at 19:30 (at the age of 36-years-old), as a single dose for COVID-19 immunisation. On 22Apr2021 at 09:00, the patient experienced sore muscles, aching joints, congestion, sore back, fever (101.8 was the highest reading), constant tiredness and inability to sleep at night. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcomes of the events sore muscles, aching joints, congestion, sore back, fever (101.8 was the highest reading), constant tiredness and inability to sleep at night were resolved on an unknown date in Apr2021.   No follow-up attempts are needed. No further information is expected.
Age: 36.0
Sex: M
Vaccine: COVID19
Symptoms: Myalgia, Nasal congestion, Pyrexia
Clinical narrative: Sore muscles; Aching joints; Congestion; Sore back; Fever (101.8 was the highest reading); Constant tiredness; Inability to sleep at night; This is a spontaneous report from a contactable consumer, the patient. A 36-year-old male patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Ew0158) via an unspecified route of administration in the left arm  on 21Apr2021 at 20:30 (at the age of 36-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history and no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Concomitant medications were not reported. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Er8737) via an unspecified route of administration in the left arm on 31Mar2021 at 19:30 (at the age of 36-years-old), as a single dose for COVID-19 immunisation. On 22Apr2021 at 09:00, the patient experienced sore muscles, aching joints, congestion, sore back, fever (101.8 was the highest reading), constant tiredness and inability to sleep at night. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcomes of the events sore muscles, aching joints, congestion, sore back, fever (101.8 was the highest reading), constant tiredness and inability to sleep at night were resolved on an unknown date in Apr2021.   No follow-up attempts are needed. No further information is expected.
Age: 63.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Decreased appetite, Headache, Hypokinesia, Nausea
Clinical narrative: Full body rash that was very itchy; Fever; Chills; Headache; Body ache; Nausea; Loss of appetite; Severe pain in left arm at injection site, causing inability to raise arm for 2 days; Severe pain in left arm at injection site, causing inability to raise arm for 2 days; This is a spontaneous report from a non-contactable consumer, the patient. A 63-year-old female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0158) via an unspecified route of administration in the left arm on 13Apr2021 (at the age of 63-years-old) as a single dose for COVID-19 immunisation. Medical history included allergy to non-steroidal anti-inflammatory drugs (NSAIDs).  Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications were not reported. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8727) via an unspecified route of administration on 23Mar2021 (at the age of 63-years-old) as a single dose for COVID-19 immunisation. The patient also previously received amoxicillin (MANUFACTURER UNKNOWN) and experienced drug allergy. On 13Apr2021 (reported as 4 to 48 hours post vaccine), the patient experienced fever, chills, headache, body ache, nausea and loss of appetite. The patient also experienced severe pain in left arm at injection site, causing inability to raise arm for 2 days. On 15Apr2021, 2 days post vaccine, the patient experienced full body rash that was very itchy. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events full body rash that was very itchy, fever, chills, headache, body ache, nausea, loss of appetite and severe pain in left arm at injection site, causing inability to raise arm for 2 days was recovering at the time of this report.   No follow-up attempts are possible. No further information is expected.
Age: 63.0
Sex: F
Vaccine: COVID19
Symptoms: Pain, Pyrexia, Rash pruritic, Vaccination site pain
Clinical narrative: Full body rash that was very itchy; Fever; Chills; Headache; Body ache; Nausea; Loss of appetite; Severe pain in left arm at injection site, causing inability to raise arm for 2 days; Severe pain in left arm at injection site, causing inability to raise arm for 2 days; This is a spontaneous report from a non-contactable consumer, the patient. A 63-year-old female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0158) via an unspecified route of administration in the left arm on 13Apr2021 (at the age of 63-years-old) as a single dose for COVID-19 immunisation. Medical history included allergy to non-steroidal anti-inflammatory drugs (NSAIDs).  Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications were not reported. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8727) via an unspecified route of administration on 23Mar2021 (at the age of 63-years-old) as a single dose for COVID-19 immunisation. The patient also previously received amoxicillin (MANUFACTURER UNKNOWN) and experienced drug allergy. On 13Apr2021 (reported as 4 to 48 hours post vaccine), the patient experienced fever, chills, headache, body ache, nausea and loss of appetite. The patient also experienced severe pain in left arm at injection site, causing inability to raise arm for 2 days. On 15Apr2021, 2 days post vaccine, the patient experienced full body rash that was very itchy. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events full body rash that was very itchy, fever, chills, headache, body ache, nausea, loss of appetite and severe pain in left arm at injection site, causing inability to raise arm for 2 days was recovering at the time of this report.   No follow-up attempts are possible. No further information is expected.
Age: 58.0
Sex: F
Vaccine: COVID19
Symptoms: Disturbance in attention, Dizziness, Fatigue, Feeling abnormal, Headache
Clinical narrative: Severe dizziness; Ringing in ears; Brain fog; Trouble concentrating; Fatigue; Nausea; Headaches; Tingling in fingers; Swollen lymph nodes; This is a spontaneous report from a contactable consumer, the patient. A 58-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6207) via an unspecified route of administration in the left arm on an unknown date, as a single dose for COVID-19 immunisation. Medical history included autoimmune disorder. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not take concomitant medications within 2 weeks of vaccination. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6203) via an unspecified route of administration in the left arm on 04 Mar2021 at 09:30 (at the age of 58-years-old) as a single dose for COVID-19 immunisation. The patient previously took trimethobenzamide hydrochloride (TIGAN) and experienced drug allergy. On 25Mar2021 the patient experienced severe dizziness, ringing in ears, brain fog, trouble concentrating, fatigue, nausea, headaches, tingling in fingers and swollen lymph nodes. The event resulted in doctor or other healthcare professional office/clinic visit. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events severe dizziness, ringing in ears, brain fog, trouble concentrating, fatigue, nausea, headaches, tingling in fingers and swollen lymph nodes was not resolved at the time of this report. . No follow-up attempts are needed. No further information is expected .
Age: 58.0
Sex: F
Vaccine: COVID19
Symptoms: Lymphadenopathy, Nausea, Paraesthesia, Tinnitus
Clinical narrative: Severe dizziness; Ringing in ears; Brain fog; Trouble concentrating; Fatigue; Nausea; Headaches; Tingling in fingers; Swollen lymph nodes; This is a spontaneous report from a contactable consumer, the patient. A 58-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6207) via an unspecified route of administration in the left arm on an unknown date, as a single dose for COVID-19 immunisation. Medical history included autoimmune disorder. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not take concomitant medications within 2 weeks of vaccination. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6203) via an unspecified route of administration in the left arm on 04 Mar2021 at 09:30 (at the age of 58-years-old) as a single dose for COVID-19 immunisation. The patient previously took trimethobenzamide hydrochloride (TIGAN) and experienced drug allergy. On 25Mar2021 the patient experienced severe dizziness, ringing in ears, brain fog, trouble concentrating, fatigue, nausea, headaches, tingling in fingers and swollen lymph nodes. The event resulted in doctor or other healthcare professional office/clinic visit. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events severe dizziness, ringing in ears, brain fog, trouble concentrating, fatigue, nausea, headaches, tingling in fingers and swollen lymph nodes was not resolved at the time of this report. . No follow-up attempts are needed. No further information is expected .
Age: 47.0
Sex: F
Vaccine: COVID19
Symptoms: Diarrhoea, Polymenorrhoea, Tinnitus
Clinical narrative: Tinnitus; Diarrhea; Shortened menstrual cycle; This is a spontaneous report from a contactable healthcare professional, the patient. A 47-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the arm left on 26Mar2021 (at the age of 47-years-old) as a single dose for COVID-19 immunisation. Medical history included postural orthostatic tachycardia syndrome and penicillin allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medication was not reported. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on an unknown date as a single dose for COVID-19 immunisation. On 27Mar2021, the patient experienced tinnitus, diarrhoea and shortened menstrual cycle. The events did not result in doctor or other healthcare professional office/clinic visits, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events tinnitus, diarrhoea and shortened menstrual cycle was not recovered at the time of this report.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 48.0
Sex: M
Vaccine: COVID19
Symptoms: Arthralgia, Asthenia, Chills, Decreased appetite, Fatigue
Clinical narrative: Injection site pain; Tiredness; Muscle pain; Joint pain/weakness; Joint tightness; Chills; Loss of appetite; joint pain/weakness; This is a spontaneous report from a contactable consumer, the patient. A 48-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 22Apr2021 at 11:15 (at the age of 48-year-old) as a single dose for COVID-19 immunisation. Medical history included covid-19. The patient had no known allergies. Prior to the vaccination, the patient was diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not receive any other medications within two weeks of vaccination. On 23Apr2021 at 05:00 the patient experienced injection site pain, tiredness, muscle pain, joint pain/weakness, joint tightness, chills and loss of appetite. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19.  The clinical outcome of the events injection site pain, tiredness, muscle pain, joint pain/weakness, joint tightness, chills and loss of appetite was resolving at the time of this report.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 48.0
Sex: M
Vaccine: COVID19
Symptoms: Joint stiffness, Myalgia, Vaccination site pain
Clinical narrative: Injection site pain; Tiredness; Muscle pain; Joint pain/weakness; Joint tightness; Chills; Loss of appetite; joint pain/weakness; This is a spontaneous report from a contactable consumer, the patient. A 48-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 22Apr2021 at 11:15 (at the age of 48-year-old) as a single dose for COVID-19 immunisation. Medical history included covid-19. The patient had no known allergies. Prior to the vaccination, the patient was diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not receive any other medications within two weeks of vaccination. On 23Apr2021 at 05:00 the patient experienced injection site pain, tiredness, muscle pain, joint pain/weakness, joint tightness, chills and loss of appetite. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19.  The clinical outcome of the events injection site pain, tiredness, muscle pain, joint pain/weakness, joint tightness, chills and loss of appetite was resolving at the time of this report.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Sex: M
Vaccine: COVID19
Symptoms: Chills, Pain, Pyrexia
Clinical narrative: Fever; Chills; Aches; This is a spontaneous report from a non-contactable consumer. An 18-year-old male patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on an unknown date as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. On 23Apr2021, the patient experienced fever, chills and aches. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events fever, chills and aches were resolved on an unknown date in Apr2021.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 55.0
Sex: F
Vaccine: COVID19
Symptoms: Muscle tightness, Pain, Pain in extremity, Peripheral swelling, Swelling face
Clinical narrative: Tightness and pain in calves; Pain in calves; Calves very swollen and painful to touch; Facial swelling; Painful to touch, painful to walk and painful to rest legs on pillows.; This is a spontaneous report from a contactable consumer, the patient. A 55-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7533) via an unspecified route of administration on 23Apr2021 (at the age of 55-years-old) as a single dose for COVID-19 immunisation. Medical history included allergy to soy, lactose, beans, pork and corn. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine Concomitant medications included paracetamol (TYLENOL), tilactase (LACTAID) and loratadine (MANUFACTURER UNKNOWN); all for an unknown indication from an unknown date and unknown if ongoing. On 24Apr2021, the patient experienced tightness and pain in calves. The patient's calves were very swollen and painful to touch, painful to walk and painful to rest her legs on pillows. The patient had some facial swelling. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcomes of the events tightness and pain in calves, calves were very swollen, painful to touch, painful to walk and painful to rest her legs on pillows and some facial swelling were not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 51.0
Sex: F
Vaccine: COVID19
Symptoms: Rash
Clinical narrative: got skin rashes all over the body; This is a spontaneous report from a contactable consumer. A 51-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EW0175) via an unspecified route of administration in the left arm  on 23Apr2021 at 11:15 at the age of 51-years-old as a single dose for COVID-19 immunisation. Medical history included penicillin allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included VITAMIN D, TRIVORA, and Multivitamins, all taken for an unknown indication, from an unknown date and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 24Apr2021, the day after the first shot, the patient experienced skin rashes all over the body except the face that looked like chicken pox not itchy though. She had chicken pox, when she was under 6-year-old and never been vaccinated for it. The patient had no fever and was less active on second day, but still there and less visible with no blood or scar. The event did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measures were taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event  got skin rashes all over the body was recovering at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 28.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Malaise, Migraine, Rash, Vomiting
Clinical narrative: 48 hours after vaccinestarted getting headache; Rash on hip; Terrible migraine; Throwing up; Delayed response; Felt a little sick; This is a spontaneous report from a contactable consumer, the patient.  A 28-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Fb-er8735) via an unspecified route of administration in the left arm on 22Apr2021 at 17:15 (at the age of 28-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient had no known allergies to medications, food or other products. The patient did not receive any vaccination within four weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications were not reported. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: F-ep7533) via an unspecified route of administration in the right arm on 31Mar2021 at 08:30 (at the age of 28-years-old) as a single dose for COVID-19 immunisation. On 24Apr2021 at 17:00, the patient experienced delayed response, felt little sick, felt better, rash on hip and terrible migraine, throwing up and then 48 hours after vaccine started getting headache. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events delayed response, felt little sick, felt better, then 48 hours after vaccine started getting headache, rash on hip and terrible migraine and throwing up were not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 55.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Diarrhoea, Dizziness, Headache, Pyrexia
Clinical narrative: Chills; Fever; Headache; Vomiting; Diarrhea; Dizziness; This is a spontaneous report from a contactable consumer. A 55-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE;Lot Number: EW0169) via an unspecified route of administration in the arm left on 22Apr2021 at 11:00 (at the age of 55-year-old) as a single dose for COVID-19 immunisation. The patient did not have any relevant medical history. Concomitant medication taken within two weeks of vaccination was not reported. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0150) via an unspecified route of administration in the left arm on 30Mar2021 at 11:00 (at the age of 55-year-old) as a single dose for COVID-19 immunisation. On 22Apr2021 at 23:30, the patient experienced chills, fever, headache, vomiting, diarrhea and dizziness. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events chills, fever, headache, vomiting, diarrhea and dizziness was recovering at the time of the report.  No follow-up attempts are needed. No further information is expected.
Age: 55.0
Sex: F
Vaccine: COVID19
Symptoms: Vomiting
Clinical narrative: Chills; Fever; Headache; Vomiting; Diarrhea; Dizziness; This is a spontaneous report from a contactable consumer. A 55-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE;Lot Number: EW0169) via an unspecified route of administration in the arm left on 22Apr2021 at 11:00 (at the age of 55-year-old) as a single dose for COVID-19 immunisation. The patient did not have any relevant medical history. Concomitant medication taken within two weeks of vaccination was not reported. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0150) via an unspecified route of administration in the left arm on 30Mar2021 at 11:00 (at the age of 55-year-old) as a single dose for COVID-19 immunisation. On 22Apr2021 at 23:30, the patient experienced chills, fever, headache, vomiting, diarrhea and dizziness. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events chills, fever, headache, vomiting, diarrhea and dizziness was recovering at the time of the report.  No follow-up attempts are needed. No further information is expected.
Age: 55.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Diarrhoea, Fatigue, Headache, Myalgia
Clinical narrative: Injection site pain; Arm pain; Tiredness; Headache; Muscle pain; Joint pain; Nausea; Vomiting; Diarrhea; This is a spontaneous report from a contactable consumer, the patient. A 55-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 09Apr2021 at 09:45 (at the age of 55-years-old) as a single dose for COVID-19 immunisation. Medical history included migraine, and adhesive allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient had received unspecified medication within two weeks of vaccination. On 09Apr2021 at 17:00, the patient experienced injection site pain and arm pain, tiredness, headache, muscle pain, joint pain, nausea and vomiting, diarrhea. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events injection site pain and arm pain, tiredness, headache, muscle pain, joint pain, nausea and vomiting, diarrhea were resolved on an unknown date in Apr2021.   No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.